Local control and survival after stereotactic body radiation therapy of early-stage lung cancer patients in Slovenia

1. Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res 2019; 11: 943–53. doi: 10.2147/CMAR.S187317 LuT YangX HuangY ZhaoM LiM MaK Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades Cancer Manag Res 2019 11 943 53 10.2147/CMAR.S187317 Open DOISearch in Google Scholar

2. Cancer in Slovenia 2019. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry; 2022. Cancer in Slovenia 2019 Ljubljana Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry 2022 Search in Google Scholar

3. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv1–21. doi: 10.1093/annonc/mdx222 PostmusPE KerrKM OudkerkM SenanS WallerDA VansteenkisteJ Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2017 28 iv1 21 10.1093/annonc/mdx222 Open DOISearch in Google Scholar

4. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) v 1, 2003. [cited 2022 Dec 28]. Available at: https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. EttingerDS WoodDE AisnerDL AkerleyW BaumanJR BharatA NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) v 1, 2003 [cited 2022 Dec 28]. Available at: https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Search in Google Scholar

5. Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy. Strahlenther Onkol 2014; 190: 26–33. doi: 10.1007/s00066-013-0450-y GuckenbergerM AndratschkeN AlheitH HolyR MoustakisC NestleU Definition of stereotactic body radiotherapy Strahlenther Onkol 2014 190 26 33 10.1007/s00066-013-0450-y Open DOISearch in Google Scholar

6. Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol 2017; 124: 11–7. doi: 10.1016/j.radonc.2017.05.012 GuckenbergerM AndratschkeN DieckmannK HoogemanMS HoyerM HurkmansC ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer Radiother Oncol 2017 124 11 7 10.1016/j.radonc.2017.05.012 Open DOISearch in Google Scholar

7. Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, et al. Stereotactic body radiation therapy for operable early-stage lung cancer findings from the NRG oncology RTOG 0618 trial. JAMA Oncol 2018; 4: 1263–6. doi: 10.1001/jamaoncol.2018.1251 TimmermanRD PaulusR PassHI GoreEM EdelmanMJ GalvinJ Stereotactic body radiation therapy for operable early-stage lung cancer findings from the NRG oncology RTOG 0618 trial JAMA Oncol 2018 4 1263 6 10.1001/jamaoncol.2018.1251 Open DOISearch in Google Scholar

8. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16: 630–7. doi: 10.1016/S1470-2045(15)70168-3 ChangJY SenanS PaulMA MehranRJ LouieAV BalterP Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials Lancet Oncol 2015 16 630 7 10.1016/S1470-2045(15)70168-3 Open DOISearch in Google Scholar

9. Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, et al. Stereotactic ablative radiotherapy for operable stage I non-small cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 2021; 22: 1448–57. doi: 10.1016/S1470-2045(21)00401-0 ChangJY MehranRJ FengL VermaV LiaoZ WelshJW Stereotactic ablative radiotherapy for operable stage I non-small cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery Lancet Oncol 2021 22 1448 57 10.1016/S1470-2045(21)00401-0 Open DOISearch in Google Scholar

10. JoLT-Ca sublobar resection (SR) versus stereotactic ablative radiotherapy (SAbR) for lung cancer (STABLE-MATES). Clinical-TrialsGov 2015. [cited 2022 Dec 28]. Available at: https://clinicaltrials.gov/ct2/show/NCT02468024 JoLT-Ca sublobar resection (SR) versus stereotactic ablative radiotherapy (SAbR) for lung cancer (STABLE-MATES) Clinical-TrialsGov 2015 [cited 2022 Dec 28]. Available at: https://clinicaltrials.gov/ct2/show/NCT02468024 Search in Google Scholar

11. Veterans affairs lung cancer surgery or stereotactic radiotherapy (VALOR). ClinicalTrialsGov 2016. [cited 2022 Dec 28]. Available at: https://clinicaltrials.gov/ct2/show/NCT02984761 Veterans affairs lung cancer surgery or stereotactic radiotherapy (VALOR) ClinicalTrialsGov 2016 [cited 2022 Dec 28]. Available at: https://clinicaltrials.gov/ct2/show/NCT02984761 Search in Google Scholar

12. Nyman J, Hallqvist A, Lund JA, Brustugun OT, Bergman B, Bergström P, et al. SPACE – a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol 2016; 121: 1–8. doi: 10.1016/j.radonc.2016.08.015 NymanJ HallqvistA LundJA BrustugunOT BergmanB BergströmP SPACE – a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC Radiother Oncol 2016 121 1 8 10.1016/j.radonc.2016.08.015 Open DOISearch in Google Scholar

13. Swaminath A, Parpia S, Wierzbicki M, Kundapur V, Faria SL, Okawara G, et al. LUSTRE: a phase III randomized trial of stereotactic body radiotherapy (SBRT) vs. conventionally hypofractionated radiotherapy (CRT) for medically inoperable stage I non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2022; 114: 1061–2. doi: 10.1016/j.ijrobp.2022.09.009 SwaminathA ParpiaS WierzbickiM KundapurV FariaSL OkawaraG LUSTRE: a phase III randomized trial of stereotactic body radiotherapy (SBRT) vs. conventionally hypofractionated radiotherapy (CRT) for medically inoperable stage I non-small cell lung cancer (NSCLC) Int J Radiat Oncol Biol Phys 2022 114 1061 2 10.1016/j.ijrobp.2022.09.009 Open DOISearch in Google Scholar

14. Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage I non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2019; 20: 494–503. doi: 10.1016/S1470-2045(18)30896-9 BallD MaiGT VinodS BabingtonS RubenJ KronT Stereotactic ablative radiotherapy versus standard radiotherapy in stage I non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial Lancet Oncol 2019 20 494 503 10.1016/S1470-2045(18)30896-9 Open DOISearch in Google Scholar

15. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010; 37: 4078–101. doi: 10.1118/1.3438081 BenedictSH YeniceKM FollowillD GalvinJM HinsonW KavanaghB Stereotactic body radiation therapy: the report of AAPM Task Group 101 Med Phys 2010 37 4078 101 10.1118/1.3438081 Open DOISearch in Google Scholar

16. Videtic GMM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, et al. A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys 2015; 93: 757–64. doi: 10.1016/j.ijrobp.2015.07.2260 VideticGMM HuC SinghAK ChangJY ParkerW OlivierKR A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927) Int J Radiat Oncol Biol Phys 2015 93 757 64 10.1016/j.ijrobp.2015.07.2260 Open DOISearch in Google Scholar

17. Adebahr S, Collette S, Shash E, Lambrecht M, Le Pechoux C, Faivre-Finn C, et al. LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective. Br J Radiol 2015; 88: 20150036. doi: 10.1259/bjr.20150036 AdebahrS ColletteS ShashE LambrechtM Le PechouxC Faivre-FinnC LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective Br J Radiol 2015 88 20150036 10.1259/bjr.20150036 Open DOISearch in Google Scholar

18. Sahgal A, Chang JH, Ma L, Marks LB, Milano MT, Medin P, et al. Spinal cord dose tolerance to stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2021; 110: 124–36. doi: 10.1016/j.ijrobp.2019.09.038 SahgalA ChangJH MaL MarksLB MilanoMT MedinP Spinal cord dose tolerance to stereotactic body radiotherapy Int J Radiat Oncol Biol Phys 2021 110 124 36 10.1016/j.ijrobp.2019.09.038 Open DOISearch in Google Scholar

19. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v5. 2021. [cited 2022 Dec 29]. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50 National Cancer Institute Common terminology criteria for adverse events (CTCAE) v5 2021 [cited 2022 Dec 29]. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50 Search in Google Scholar

20. Peterlin P, Stanič K, Méndez I, Strojnik A. Treating lung cancer with dynamic conformal arc therapy: a dosimetric study. Radiat Oncol 2017; 12: 93. doi: 10.1186/s13014-017-0823-y PeterlinP StaničK MéndezI StrojnikA. Treating lung cancer with dynamic conformal arc therapy: a dosimetric study Radiat Oncol 2017 12 93 10.1186/s13014-017-0823-y Open DOISearch in Google Scholar

21. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi, G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009; 27: 3290–6. doi: 10.1200/JCO.2008.21.5681 BaumannP NymanJ HoyerM WennbergB GagliardiG LaxI Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy J Clin Oncol 2009 27 3290 6 10.1200/JCO.2008.21.5681 Open DOISearch in Google Scholar

22. Singh AK, Gomez-Suescun JA, Stephans KL, Bogart JA, Hermann GM, Tian L, et al. One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial. Int J Radiat Oncol Biol Phys 2019; 105: 752–9. doi: 10.1016/j.ijrobp.2019.08.019 SinghAK Gomez-SuescunJA StephansKL BogartJA HermannGM TianL One versus three fractions of stereotactic body radiation therapy for peripheral stage I to II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial Int J Radiat Oncol Biol Phys 2019 105 752 9 10.1016/j.ijrobp.2019.08.019 Open DOISearch in Google Scholar

23. Videtic GM, Paulus R, Singh AK, Chang JY, Parker W, Olivier KR, et al. Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2019; 103: 1077–84. doi: 10.1016/j.ijrobp.2018.11.051 VideticGM PaulusR SinghAK ChangJY ParkerW OlivierKR Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer Int J Radiat Oncol Biol Phys 2019 103 1077 84 10.1016/j.ijrobp.2018.11.051 Open DOISearch in Google Scholar

24. Timmerman RD, Hu C, Michalski JM, Bradley JC, Galvin J, Johnstone DW, et al. Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer. JAMA Oncol 2018; 4: 1287–8. doi: 10.1001/jamaoncol.2018.1258 TimmermanRD HuC MichalskiJM BradleyJC GalvinJ JohnstoneDW Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer JAMA Oncol 2018 4 1287 8 10.1001/jamaoncol.2018.1258 Open DOISearch in Google Scholar

25. Taremi M, Hope A, Dahele M, Pearson S, Fung S, Purdie T, et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. Int J Radiat Oncol Biol Phys 2012; 82: 967–73. doi: 10.1016/j.ijrobp.2010.12.039 TaremiM HopeA DaheleM PearsonS FungS PurdieT Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients Int J Radiat Oncol Biol Phys 2012 82 967 73 10.1016/j.ijrobp.2010.12.039 Open DOISearch in Google Scholar

26. Singh D, Chen Y, Hare MZ, Usuki KY, Zhang H, Lundquist T, et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. J Thorac Dis 2014; 6: 369–74. doi: 10.3978/j.issn.2072-1439.2013.12.03 SinghD ChenY HareMZ UsukiKY ZhangH LundquistT Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung J Thorac Dis 2014 6 369 74 10.3978/j.issn.2072-1439.2013.12.03 Open DOISearch in Google Scholar

27. Abreu CECV, Moraes FY, Miranda FA, Siqueira GSM, Gadia R, Haddad CK, et al. Stereotactic body radiation therapy for biopsy-proven primary non-small-cell lung cancer: experience of patients with inoperable cancer at a single brazilian institution. J Glob Oncol 2018; 4: 1–8. doi: 10.1200/JGO.18.00020 AbreuCECV MoraesFY MirandaFA SiqueiraGSM GadiaR HaddadCK Stereotactic body radiation therapy for biopsy-proven primary non-small-cell lung cancer: experience of patients with inoperable cancer at a single brazilian institution J Glob Oncol 2018 4 1 8 10.1200/JGO.18.00020 Open DOISearch in Google Scholar

28. Doupnik NP, Hirmiz K, Hussein AA, Agapito J, Pan M. Early-stage non-small cell lung cancer stereotactic body radiation therapy outcomes in a single institution. Cureus 2022; 14: e21878. doi: 10.7759/cureus.21878 DoupnikNP HirmizK HusseinAA AgapitoJ PanM. Early-stage non-small cell lung cancer stereotactic body radiation therapy outcomes in a single institution Cureus 2022 14 e21878 10.7759/cureus.21878 Open DOISearch in Google Scholar

29. Lackey A, Donington JS. Surgical management of lung cancer. Semin Intervent Radiol 2013; 30: 133–40. doi: 10.1055/s-0033-1342954 LackeyA DoningtonJS. Surgical management of lung cancer Semin Intervent Radiol 2013 30 133 40 10.1055/s-0033-1342954 Open DOISearch in Google Scholar

30. Zadnik V, Žagar T, Tomšič S, Lokar K, Duratović Konjević A, Zakotnik B. Survival of cancer patients, diagnosed in 1997–2016 in Slovenia. Ljubljana: Institute of Oncology Ljubljana; 2021. ZadnikV ŽagarT TomšičS LokarK Duratović KonjevićA ZakotnikB. Survival of cancer patients, diagnosed in 1997–2016 in Slovenia Ljubljana Institute of Oncology Ljubljana 2021 Search in Google Scholar

31. Bitenc M, Cufer T, Kern I, Miklavcic M, Petrovic S, Groznik v, Sadikov A. Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer. Radiol Oncol 2022; 56: 346–54. doi: 10.2478/raon-2022-0030 BitencM CuferT KernI MiklavcicM PetrovicS Groznikv SadikovA. Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer Radiol Oncol 2022 56 346 54 10.2478/raon-2022-0030 Open DOISearch in Google Scholar

32. Mullins K. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: when and why is it appropriate therapy? J Adv Pract Oncol 2015; 6: 351–4. doi: 10.6004/jadpro/2015.6.4.5 MullinsK. Stereotactic body radiotherapy for early-stage non-small cell lung cancer: when and why is it appropriate therapy? J Adv Pract Oncol 2015 6 351 4 10.6004/jadpro/2015.6.4.5 Open DOISearch in Google Scholar

33. Haasbeek CJA, Palma D, Visser O, Lagerwaard FJ, Slotman B, Senan S. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol 2012; 23: 2743–7. doi: 10.1093/annonc/mds081 HaasbeekCJA PalmaD VisserO LagerwaardFJ SlotmanB SenanS. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands Ann Oncol 2012 23 2743 7 10.1093/annonc/mds081 Open DOISearch in Google Scholar

34. von Reibnitz D, Shaikh F, Wu AJ, Treharne GC, Dick-Godfrey R, Foster A, et al. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC). Acta Oncol 2018; 57: 1567–73. doi: 10.1080/0284186X.2018.1481292 von ReibnitzD ShaikhF WuAJ TreharneGC Dick-GodfreyR FosterA Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC) Acta Oncol 2018 57 1567 73 10.1080/0284186X.2018.1481292 Open DOISearch in Google Scholar

35. Ishikura S. Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges. Gen Thorac Cardiovasc Surg 2012; 60: 127–31. doi: 10.1007/s11748-011-0832-y IshikuraS. Optimal radiotherapy for non-small-cell lung cancer: current progress and future challenges Gen Thorac Cardiovasc Surg 2012 60 127 31 10.1007/s11748-011-0832-y Open DOISearch in Google Scholar

36. Wegner RE, Ahmed N, Hasan S, Schumacher LY, Van Deusen M, Colonias A. SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions. Lung Cancer Manag 2018; 7: LMT01. doi: 10.2217/lmt-2018-0006 WegnerRE AhmedN HasanS SchumacherLY Van DeusenM ColoniasA. SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions Lung Cancer Manag 2018 7 LMT01 10.2217/lmt-2018-0006 Open DOISearch in Google Scholar

37. Haidar YM, Rahn DA, Nath S, Song W, Bazhenova L, Makani S, et al. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Ther Adv Respir Dis 2014; 8: 3–12. doi: 10.1177/1753465813512545 HaidarYM RahnDA NathS SongW BazhenovaL MakaniS Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation Ther Adv Respir Dis 2014 8 3 12 10.1177/1753465813512545 Open DOISearch in Google Scholar

38. Hasan S, Colonias A, Mickus T, VanDeusen M, Rodney E. Wegner RE, et al. Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: predictors from a 10 year single institution experience. Thorac Cancer 2018; 9: 699–706. doi: 10.1111/1759-7714.12635 HasanS ColoniasA MickusT VanDeusenM RodneyE WegnerRE Image-based management of empiric lung stereotactic body radiotherapy (SBRT) without biopsy: predictors from a 10 year single institution experience Thorac Cancer 2018 9 699 706 10.1111/1759-7714.12635 Open DOISearch in Google Scholar

39. IJsseldijk MA, Shoni M, Siegert C, Wiering B, van Engelenburg KCA, Lebenthal A, et al. Survival after stereotactic body radiation therapy for clinically diagnosed or biopsy-proven early-stage NSCLC: a systematic review and meta-analysis. J Thorac Oncol 2019; 14: 583–95. doi: 10.1016/j.jtho.2018.12.035 IJsseldijkMA ShoniM SiegertC WieringB van EngelenburgKCA LebenthalA Survival after stereotactic body radiation therapy for clinically diagnosed or biopsy-proven early-stage NSCLC: a systematic review and meta-analysis J Thorac Oncol 2019 14 583 95 10.1016/j.jtho.2018.12.035 Open DOISearch in Google Scholar

40. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007; 2: S94–100. doi: 10.1097/JTO.0b013e318074de34 OnishiH ShiratoH NagataY HiraokaM FujinoM GomiK Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study J Thorac Oncol 2007 2 S94 100 10.1097/JTO.0b013e318074de34 Open DOISearch in Google Scholar

41. Zhang J, Yang F, Li B, Li H, Liu J, Huang W, et al. Which is the optimal biologically effective dose of stereotactic body radiotherapy for stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 2011; 81: e305–16. doi: 10.1016/j.ijrobp.2011.04.034 ZhangJ YangF LiB LiH LiuJ HuangW Which is the optimal biologically effective dose of stereotactic body radiotherapy for stage I non-small-cell lung cancer? A meta-analysis Int J Radiat Oncol Biol Phys 2011 81 e305 16 10.1016/j.ijrobp.2011.04.034 Open DOISearch in Google Scholar

42. Koshy M, Malik R, Weichselbaum RR, Sher DJ. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2015; 91: 344–50. doi: 10.1016/j.ijrobp.2014.10.002 KoshyM MalikR WeichselbaumRR SherDJ. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small cell lung cancer Int J Radiat Oncol Biol Phys 2015 91 344 50 10.1016/j.ijrobp.2014.10.002 Open DOISearch in Google Scholar

43. Alite F, Stang K, Balasubramanian N, Adams W, Shaikh MP, Small C, et al. Local control dependence on consecutive vs. nonconsecutive fractionation in lung stereotactic body radiation therapy. Radiother Oncol 2016; 121: 9–14. doi: 10.1016/j.radonc.2016.07.026 AliteF StangK BalasubramanianN AdamsW ShaikhMP SmallC Local control dependence on consecutive vs. nonconsecutive fractionation in lung stereotactic body radiation therapy Radiother Oncol 2016 121 9 14 10.1016/j.radonc.2016.07.026 Open DOISearch in Google Scholar

44. Ikawa T, Tabuchi T, Konishi K, Morimoto M, Hirata T, Kanayama N, et al. Prolonged overall treatment time negatively affects the outcomes of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: a propensity score-weighted, single-center analysis. PLoS One 2021; 16: e0253203. doi: 10.1371/journal.pone.0253203 IkawaT TabuchiT KonishiK MorimotoM HirataT KanayamaN Prolonged overall treatment time negatively affects the outcomes of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: a propensity score-weighted, single-center analysis PLoS One 2021 16 e0253203 10.1371/journal.pone.0253203 Open DOISearch in Google Scholar